Shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) were up 3.5% during mid-day trading on Wednesday . The company traded as high as $27.24 and last traded at $26.85, with a volume of 479,196 shares traded. The stock had previously closed at $25.95.

A number of analysts have recently issued reports on AMAG shares. Jefferies Group reissued a “buy” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, June 2nd. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. Deutsche Bank AG reduced their price objective on shares of AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating for the company in a research note on Monday, May 9th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $37.00 price objective on shares of AMAG Pharmaceuticals in a research note on Thursday, May 5th. Finally, Raymond James Financial Inc. cut shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 4th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.20.

The company has a market capitalization of $926.34 million and a PE ratio of 89.60. The firm has a 50-day moving average price of $23.92 and a 200 day moving average price of $23.54.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 EPS for the quarter, missing analysts’ consensus estimates of $1.11 by $0.17. The company had revenue of $117.60 million for the quarter, compared to the consensus estimate of $124.83 million. During the same period in the previous year, the business earned $1.17 EPS. The firm’s quarterly revenue was up 41.9% compared to the same quarter last year. Equities research analysts expect that AMAG Pharmaceuticals Inc. will post $5.20 EPS for the current year.

A number of hedge funds have made changes to their positions in the stock. Rhumbline Advisers boosted its stake in shares of AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 3,420 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock valued at $1,498,000 after buying an additional 42,208 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock valued at $1,893,000 after buying an additional 3,903 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock valued at $12,010,000 after buying an additional 8,435 shares during the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.